Effect of vitamin C on oxidative liver injury due to isoniazid in rats

Pediatrics International

Volumn 52, Issue 1, 2010, Pages 69-74

  Ergul, Yakup ^a   Erkan, Tulay ^a   Uzun, Hafize ^a   Genc, Habibe ^a   Altug, Tuncay ^a   Erginoz, Ethem ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Glutathione; Hepatotoxicity; Isoniazid; Oxidative stress; Vitamin C

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; ISONIAZID; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; ERYTHROCYTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIOXIDANTS; ANTITUBERCULAR AGENTS; ASCORBIC ACID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; GLUTATHIONE; GLUTATHIONE PEROXIDASE; ISONIAZID; LIVER FUNCTION TESTS; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE;

EID: 76249097042     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2009.02891.x     Document Type: Article

References (27)

1. Attri S, Rana SV, Vaiphei K et al. Isoniazid-and rifampicin-induced oxidative hepatic injury: protection by n-acetylcysteine. Hum. Exp. Toxicol. 2000 19: 517 522.
2. Sarich TC, Youssefi M, Zhou T, Adams SP, Wall RA, Wright JM. Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits. Arch. Toxicol. 1996 70: 835 840.
3. Sarich TC, Zhou T, Adams SP, Bain AI, Wall RA, Wright JM. A model of isoniazid-induced hepatotoxicity in rabbits. J. Pharmacol. Toxicol. Methods 1995 34: 109 116.
4. Sarich TC, Adams SP, Petricca G, Wright JM. Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. J. Pharmacol. Exp. Ther. 1999 289: 695 702.
5. Yue J, Peng RX, Yang J, Kong R, Liu J. CYP2E1 mediated isoniazid-induced hepatotoxicity in rats. Acta Pharmacol. Sin. 2004 25: 699 704.
6. Sodhi CP, Rana SV, Mehta SK, Vaiphei K, Attari S, Mehta S. Study of oxidative-stress in isoniazid-rifampicin induced hepatic injury in young rats. Drug Chem. Toxicol. 1997 20: 255 269.
7. Arrigoni O, De Tullio MC. Ascorbic acid: Much more than just an antioxidant. Biochim. Biophys. Acta 2002 1569: 1 9.
8. Beutler E, Duran O, Kelly MB. Improved method for the determination of blood glutathione. J. Lab. Clin. Med. 1963 51: 882 888.
9. Sun Y, Oberly LW, Ying LA. Simple method for clinical assay of superoxide dismutase. Clin. Chem. 1988 34: 497 500.
10. Bernstein J, Lott WA, Steinberg BA, Yale HL. Chemotherapy of experimental tuberculosis. Isonicotinic acid hydrazide (nydrazid) and related compounds. Am. Rev. Tuberc. 1952 65: 357 364.
11. Lees AW, Allan GW, Smith J, Tyrrell WF, Fallon RJ. Toxicity form rifampicin plus isoniazid and rifampicin plus ethambutol therapy. Tubercle 1971 52: 182 190.
12. Bistritzer T, Barzilay Z, Jonas A. Isoniazid-rifampin-induced fulminant liver disease in an infant. J. Pediatr. 1980 97: 480 482.
13. Mitchell JR, Thorgeirsson UP, Black M et al. Increased incidence of isoniazid hepatitis in rapid acetylators: Possible relation to hydrazine metabolites. Clin. Pharmacol. Ther. 1975 18: 70 9.
14. Ellard GA. The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis. Tubercle 1984 65: 211 227.
15. Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin. Pharmacol. Ther. 1976 19: 610 625.
16. Gurumurthy P, Krishnamurthy MS, Nazareth O, et al. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am. Rev. Respir. Dis. 1984 129: 58 61.
17. 4 hepatotoxicity: A preliminary report. Hum. Exp. Toxicol. 1994 13: 107 109.
18. 4-induced lipid peroxidation and hepatotoxicity. Chem. Biol. Interact. 1985 55: 327 334.
19. Sodhi CP, Rana SV, Mehta SK et al. Study of oxidative stress in isoniazid-induced hepatic injury in young rats with and without protein energy malnutrition. J. Biochem. Toxicol. 1996 11: 139 146.
20. Nelson SD, Mitchell JR, Timbrell JA, Snodgrass WR, Corcoran GB. Isoniazid and iproniazid: Activation of metabolites to toxic intermediates in man and rat. Science 1976 193: 901 903.
21. Tahan V, Ozaras R, Canbakan B et al. Melatonin reduces dimethylnitrosamine-induced liver fibrosis in rats. J. Pineal Res. 2004 37: 78 84.
22. George J. Ascorbic acid concentrations in dimethylnitrosamine-induced hepatic fibrosis in rats. Clin. Chim. Acta 2003 335: 39 47.
23. Cabre M, Camps J, Paternain JL, Ferre N, Joven J. Time-course of changes in hepatic lipid peroxidation and glutathione metabolism in rats with carbon tetrachloride induced cirrhosis. Clin. Exp. Pharmacol. Physiol. 2000 27: 694 699.
24. Beattie AD, Sherlock S. Ascorbic acid deficiency in liver disease. Gut 1976 17: 571 575.
25. Yamamoto Y, Yamashita S, Fujisawa A, Kokura S, Yoshikawa T. Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem. Biophys. Res. Commun. 1998 247: 166 170.
26. Matsuki Y, Akazawa M, Tsuchiya K, Sakurai H, Kiwada H, Goromaru T. Effects of ascorbic acid on the free radical formations of isoniazid and its metabolites. Yakugaku Zasshi 1991 111: 600 605.
27. Seo MY, Lee SM. Protective effect of low dose of ascorbic acid on hepatobiliary function in hepatic ischemia/reperfusion in rats. J. Hepatol. 2002 36: 72 7.